01—Abstract
Summary
Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) announced through an 8-K filing on August 5, 2026, the closing of a significant debt offering totaling approximately $9.93 billiona in net proceeds.
This substantial capital raise comprises multiple tranches of senior notes with varying maturities and interest rates, including floating rate notes, fixed-rate notes ranging from 2028 to 2066. The primary purpose of this offering is to fund a portion of the cash payment obligations related to AbbVie's acquisition of Apogee Therapeutics, Inc. This strategic move underscores AbbVie's commitment to its growth strategy through significant M&A activity. The proceeds will also be used for other general corporate purposes, potentially including debt repayment or repurchase, and will reduce commitments under an existing term loan facility established for the Apogee acquisition.
02—Key points
Key Highlights
- AbbVie raised approximately $9.93 billion in net proceeds from the issuance of various senior notes.
- The debt offering includes a mix of floating rate notes and fixed-rate notes with maturities spanning from 2028 to 2066.
- The net proceeds are primarily earmarked to finance part of the cash consideration for the acquisition of Apogee Therapeutics, Inc.
- The offering also allows for general corporate purposes, which may include debt reduction.
- This capital raise reduces AbbVie's reliance on a previously established $10.0 billion term loan facility for the Apogee acquisition.
- The underwriting agreement with major financial institutions, including Morgan Stanley, BofA Securities, and J.P. Morgan, contains customary representations, warranties, and indemnification clauses.
03—Questions
Frequently Asked Questions
What is the main purpose of this debt offering?
The primary purpose of this debt offering is to fund a portion of the cash payment obligations related to AbbVie's acquisition of Apogee Therapeutics, Inc., as well as for other general corporate purposes, which may include debt repayment or repurchase.
How much money did AbbVie raise from this offering?
AbbVie is expected to receive approximately $9.93 billion in net proceeds from the sale of the various senior notes.
What types of notes were issued, and what are their maturities?
AbbVie issued senior floating rate notes due 2028, along with fixed-rate senior notes due in 2028, 2030, 2031, 2033, 2036, 2038, 2056, and 2066, with coupon rates ranging from 4.500% to 6.100%.
How does this offering affect AbbVie's existing credit facilities?
The net proceeds from this issuance will reduce commitments under AbbVie's $10.0 billion 364-day delayed draw term loan facility that was entered into in connection with the acquisition of Apogee Therapeutics.
04—Continue